2O9 Stock Chart & Stats
€0.03
>-€0.01(-3.45%)
At close: 4:00 PM EDT
€0.03
>-€0.01(-3.45%)
Day’s Range― - ―
52-Week Range€0.01 - €0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€13.53M
Enterprise Value€22.35
Total Cash (Recent Filing)€6.20M
Total Debt (Recent Filing)€5.80M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding437,018,680
10 Day Avg. Volume52
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€1.33M
Bulls Say, Bears Say
Bulls Say
Proprietary Diagnostic + AI AlgorithmKidneyIntelX pairs biomarker assays with an AI-enabled algorithm to deliver clinical decision support for diabetic kidney risk. That combination creates a durable product differentiation and clinical utility that supports adoption by providers and payers, raising switching costs and underpinning recurring per-test demand as care pathways evolve.
Improving Revenue And Gross Margin TrajectoryA meaningful lift in revenue and a step-change gross margin demonstrate improving unit economics of the lab and test offering. Sustainable margin expansion at scale would enable operating leverage, making future incremental revenue more profitable and supporting long-term viability if volume growth continues.
Per-test Reimbursement And Health-system ContractsA per-test reimbursement model and direct contracts with health systems provide a repeatable commercialization path and revenue visibility as tests are adopted. Durable payer coverage and system agreements can create predictable volume channels and align incentives for disease-management programs over multiple quarters.
Bears Say
Negative Equity And Stressed CapitalizationNegative shareholders' equity reflects cumulative losses and constrains financial flexibility. It increases dependency on external financing, can complicate contracting or partnership negotiations, and is a structural headwind to scaling operations without recurring positive cash flow or material capital injections.
Persistent Heavy Cash BurnSustained negative operating and free cash flow requires ongoing financing to fund growth and operations. Even with improvement, the absolute burn relative to revenue scale shortens runway, forces dilution or costly capital raises, and distracts management from commercial execution and scaling clinical adoption.
Profitability Far From BreakevenAn extremely negative net margin signals a cost structure misaligned with current revenues: fixed lab, R&D, and commercial costs far exceed test income. Until volume rises materially or costs are restructured, the business cannot self-fund growth, limiting long-term sustainability and constraining strategic options.
Renalytix News
2O9 FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was €0.01 and its highest was €0.13 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is €13.53M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 91 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -€0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.636%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in DE:2O9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc specializes in developing cutting-edge in vitro diagnostic solutions for kidney diseases, leveraging the power of artificial intelligence. Their primary offering, KidneyIntelX, is an advanced diagnostic platform. It employs a sophisticated AI-enabled algorithm that synthesizes various data streams, such as scientifically validated blood biomarkers, inherited genetic factors, and personalized patient data extracted from electronic health record systems. The output is a unique, individualized risk score for each patient. These innovative tools serve multiple critical functions: they assist in the diagnosis and prognosis of kidney ailments, optimize clinical patient management, facilitate patient stratification for pharmaceutical clinical trials, and aid in the discovery of novel drug targets. The company has secured several pivotal license agreements. A partnership with Mount Sinai Health System grants rights for the development and commercialization of AI applications in kidney disease diagnostics. Another agreement with Joslin Diabetes Center, Inc. focuses on creating and marketing biomarker-based products for the diagnosis and prediction of kidney conditions. Furthermore, Renalytix holds a license with Kantaro Biosciences LLC for laboratory assays designed to detect SARS-CoV-2 antibodies. In a collaborative effort, Renalytix has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine. This alliance aims to implement an advanced clinical care paradigm, specifically designed to enhance kidney health and mitigate the progression of kidney disease and subsequent renal failure in high-risk patient populations. Founded in 2018, the company operated under the name Renalytix AI plc until its change to Renalytix Plc in June 2021. Its corporate headquarters are situated in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―